Market Newsdesk

CHATHAM, N.J., May 09, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-6.25 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 10, 2023.

The reverse stock split was previously approved by the Board of Directors of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading price of Tonix’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market (Rule 5550(a)(1)). Tonix’s common stock will continue to trade on the NASDAQ Capital Market under the symbol “TNXP” and under a new CUSIP number, 890260854. As a result of the reverse stock split, every six and one-quarter pre-split shares of common stock outstanding will become one share of common stock. The reverse stock split will also proportionately reduce the number of shares of authorized common stock from 1 billion to 160 million shares. The reverse split will also apply to common stock issuable upon the exercise of Tonix’s outstanding warrants and stock options.

Tonix’s transfer agent, VStock Transfer LLC, which is also acting as the exchange agent for the reverse split, will provide instructions to shareholders regarding the process for exchanging share certificates. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole post-split share and no shareholders will receive cash in lieu of fractional shares.

Tonix Pharmaceuticals Holding Corp.

^*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), in development for chronic migraine, is currently enrolling with topline data expected in the fourth quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets), a once-daily formulation being developed as a treatment for major depressive disorder (MDD), is also currently enrolling with interim data expected in the fourth quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the third quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox, for which a Phase 1 study is expected to be initiated in the second half of 2023. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease portfolio also includes TNX-3900 and TNX-4000, classes of broad-spectrum small molecule oral antivirals.

^*

All of Tonix’s product candidates are investigational new drugs or biologics and none has been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
[email protected]
(862) 904-8182

Maddie Stabinski (media)
Russo Partners
[email protected]
(212) 845-4273

Peter Vozzo (investors)
ICR Westwicke
[email protected]
(443) 213-0505

May 9, 2023

Amsterdam, the Netherlands –

Royal Philips
(NYSE: PHG, AEX: PHIA) announced that today’s Annual General Meeting of Shareholders (2023 AGM) has reappointed Abhijit Bhattacharya for a two year’s term as member of the Board of Management fulfilling the role of CFO, and reappointed Liz Doherty and David Pyott as members of the Supervisory Board. With these reappointments, the composition of the Supervisory Board committees remains unchanged.

Other voting items, such the company’s proposed dividend of EUR 0.85 per share over 2022, [1] the proposal to reappoint EY as the company’s external auditor for a term of one year starting January 1, 2024, and the proposal to appoint PricewaterhouseCoopers as the company’s new external auditor for a term of four years starting January 1, 2025, as well as a number of recurring items, including the proposal to adopt the company’s financial statements, [2] were also approved. Additionally, the AGM approved the advisory voting item on the 2022 Remuneration Report.

Shareholders voted against the discharge of the collective members of the Board of Management. This follows the voting guidance from certain proxy advisors to signal discontent in respect of one former member of the Board of Management.

“Following the recent changes made in the Executive Committee, I am pleased that Abhijit is adding a two-year’s term to his tenure as CFO, thereby ensuring continuity and enabling a smooth succession process in parallel,” said Feike Sijbesma, Chairman of the Supervisory Board of Royal Philips. “I am also pleased that Liz and David will continue to serve as members of the Supervisory Board and support Philips with their much-valued expertise and counsel.”

Mr. Sijbesma continued: “We appreciate the support expressed by the shareholders regarding current management and direction of Philips. Under the leadership of its new CEO Roy Jakobs, Philips is fully focused on implementing the plan to create value with sustainable impact for our shareholders and all other stakeholders.”

In January 2023, Philips CEO Roy Jakobs and his team presented the company’s plan to create value with sustainable impact. Philips is executing to plan on its three priorities to improve execution by enhancing patient safety & quality, strengthening its supply chain reliability, and establishing a simplified, more agile operating model.

Additional information on the composition of the Board of Management, the Executive Committee and the Supervisory Board can be found here. For more information about Philips’ 2023 AGM, please click on this link.

[1]    Further details about the dividend can be found via this link.
[2]    Philips’ 2022 financial statements are included in its 2022 Annual Report that was published on February 21, 2023.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 615213446
E-mail: [email protected]

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips AGM 2023

EVERETT, Wash., May 09, 2023 (GLOBE NEWSWIRE) — Coastal Financial Corporation (NASDAQ: CCB), the parent company of Coastal Community Bank, was awarded the Raymond James Community Bankers Cup for 2022. Coastal has received the award for the fourth consecutive year.

The 11th annual Raymond James Community Bankers Cup recognizes the top 10% of community banks based on various profitability, operational efficiency, and balance sheet metrics. The pool of banks considered for recognition includes all exchange-traded domestic banks, excluding mutual holding companies and potential acquisition targets, with assets between $500 million and $10 billion as of December 31, 2022.

“The Raymond James Community Bankers Cup is a prestigious award, and to receive it for the fourth consecutive year is an incredible honor,” remarked Eric Sprink, CEO of Coastal Financial Corporation. He continued, “Our success is due to the dedication and resilience of the Coastal team, who have gone above and beyond in supporting our communities and thousands of small businesses, expanding our community bank, and developing our CCBX division.”

About Coastal Financial Corporation

Coastal Financial Corporation (NASDAQ: CCB), is an Everett, Washington-based Bank holding company with Coastal Community Bank (the “Bank”) a full-service commercial bank, as its sole wholly owned banking subsidiary. The Bank operates through its 14 branches in Snohomish, Island, and King Counties, the Internet, and its mobile banking application. The Bank, through its CCBX division, provides banking as a service (“BaaS”) that allows our broker-dealer and digital financial service partners to offer their customers banking services. As of March 31, 2023, we had total assets of $3.45 billion, total gross loans, including loans held for sale, of $2.84 billion, total deposits of $3.10 billion, and total shareholders’ equity of $258.8 million. To learn more about Coastal Community Bank visit www.coastalbank.com. Member FDIC.

NEWTOWN, Pa., May 09, 2023 (GLOBE NEWSWIRE) — The law firm of Edelson Lechtzin LLP reminds purchasers of Medical Properties Trust, Inc. (“MPT” or the “Company”) (NYSE: MPW) common stock between March 1, 2022, and February 22, 2023, both dates inclusive (the “Class Period”) that only 34 days remain until the lead plaintiff deadline.

Investors who purchased Medical Properties Trust, Inc. common stock may move the U.S. District Court for the Southern District of New York to appoint them as lead plaintiff, no later than June 12, 2023. Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected]. A copy of the class action complaint can be viewed HERE.

Background on Medical Properties Trust, Inc.

MPT, headquartered in Birmingham, Alabama, is a real estate investment trust that leases its facilities to providers of healthcare services, including long-term acute care hospitals, regional and community hospitals, medical office buildings, and rehabilitation hospitals.

The Securities Fraud Claims

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects, including that Prospect Medical Holdings, Inc. (“Prospect”), a healthcare services company that leases and operates 13 of MPT’s facilities, was facing significant pressures affecting the profitability of its Pennsylvania properties. Consequently, there was a significant risk that Prospect would be unable to meet rental obligations it owed to MPT. At the time, Prospect was MPT’s third largest tenant. As a result, “given the elongated timing of the Pennsylvania recovery,” the Company was reasonably likely to record an impairment charge to the real estate value of the Pennsylvania properties.

On February 23, 2023, before the markets opened, MPT issued a press release detailing its fourth quarter and full year 2022 financial results. MPT disclosed an impairment of about $171 million on four properties leased to Prospect as well as a write-off of almost $112 million in unbilled rent for the same client. On this news, MPT’s stock price plummeted $0.80, or 8.7%, to close at $11.14 per share on February 23, 2023, injuring investors.

MPW shares have failed to recover losses since these disclosures. As of the May 8, 2023 market close, MPW stock was trading at $8.57 per share.

For more information, please contact:

Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: [email protected]
Email: [email protected]  
Web: www.edelson-law.com

Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation in cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, data breaches, consumer fraud, and dangerous and defective drugs and medical devices.

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

KUALA LUMPUR, MALAYSIA, May 09, 2023 (GLOBE NEWSWIRE) — Evergreen Corporation (Nasdaq: EVGR) (the “Company”) today announced that the extraordinary general meeting of shareholders of the Company (the “Extraordinary General Meeting”), originally scheduled for 9:00 a.m. Eastern Time on May 9, 2023, was convened and then adjourned, without conducting any business, to recommence at 11:00 a.m. Eastern Time on May 10, 2023 as a virtual meeting via live webcast at https://www.cstproxy.com/evergreencorporation/2023 and the offices of Evergreen Corporation, Lot 1.02, Level 1, Glo Damansara, 699, Jalan Damansara, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia.

The Extraordinary General Meeting is being held for the purposes of considering and voting on the following proposals:

Each of the foregoing proposals is described in more detail in the definitive proxy statement related to the Extraordinary General Meeting filed by the Company with the Securities and Exchange Commission (the “SEC”) on May 2, 2023, as amended and supplemented on May 3, 2023, May 4, 2023 and May 5, 2023 (the “Definitive Proxy Statement”).

The record date for the Extraordinary General Meeting remains the close of business on May 2, 2023. Shareholders who have not submitted their proxy for the Extraordinary General Meeting, or who wish to change or revoke their proxy, are urged to do so promptly. Shareholders who have previously submitted their proxy and do not wish to change or revoke their proxy need not take any action. If you are a shareholder of record and have questions or need assistance voting your shares, please contact the Company’s proxy solicitor at: Advantage Proxy, Inc., PO Box 10904, Yakima, WA 98909, phone: 866-894-0536, email: [email protected]. Further information related to attendance, voting and the proposals to be considered and voted on at the Extraordinary General Meeting is described in the Definitive Proxy Statement.

About Evergreen Corporation

The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on technology companies involved in Artificial Intelligence (AI), FinTech and Financial Services, the Metaverse, the Internet of Things (IoT), eCommerce, social commerce, Industry 4.0 (IR4.0), as well as areas surrounding the new digital economy, in the ASEAN region. The Company is led by Liew Choon Lian, the Company’s Chairman of the Board and Chief Executive Officer.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. Such statements may include, but are not limited to, statements regarding the approval of certain proposals at the Extraordinary General Meeting or the implementation of the Extension. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly, including those risks set forth in the Definitive Proxy Statement, the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other documents filed with the SEC. Copies of such filings are available on the SEC’s website at www.sec.gov. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

Additional Information and Where to Find It

Investors and security holders of the Company are advised to read the Definitive Proxy Statement because it contains important information about the Extraordinary General Meeting and the Company. Investors and security holders of the Company may also obtain a copy of the Definitive Proxy Statement, as well as other relevant documents that have been or will be filed by the Company with the SEC, without charge and once available, at the SEC’s website at www.sec.gov, or by written request to the Company at Evergreen Corporation, Lot 1.02, Level 1, Glo Damansara, 699, Jalan Damansara, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia.

Participants in the Solicitation

The Company and certain of its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in respect of the proposals to be considered and voted on at the Extraordinary General Meeting. Information concerning the interests of the directors and executive officers of the Company is set forth in the Definitive Proxy Statement, which may be obtained free of charge from the sources indicated above.

Contact

Liew Choon Lian
Chief Executive Officer
Email: [email protected]
Phone: +1 786 406 6082